关键词: 多发性骨髓瘤, 硼替佐米, 带状疱疹, 伐昔洛韦

Abstract:

Background and purpose: Herpes zoster is a common adverse event associated with the use of bortezomib. The objective of this study was to evaluate the efficacy of different therapeutic regimens of valacyclovir prophylaxis: continuously administration and intermittent administration. Methods: We retrospectively analyzed the efficacy, side effects, expense of valacyclovir and emotional states of 31 patients with multiple myeloma who received bortezomib and valacyclovir prophylaxis. Among them, 14 patients underwent continuously administration of valacyclovir, the other 17 patients underwent intermittent administration. Continuously administration was defined as daily oral valacyclovir 600 mg without cessation during entire period of bortezomib treatment. Intermittent administration was defined as patients received valacyclovir at a dose of 600 mg daily during chemotherapy, while discontinue valacyclovir at the intermission time of bortezomib treatment. Results: There were no herpes zoster in patients of 2 arms. Adverse events over grade 3 associated with valacyclovir were not observed. Intermittent administration of valacyclovir showed a superiority of economic benefit. The emotional status were depended on the therapeutic effects of multiple myeloma. For those relapsed or refractory patients, continuously administration of valacyclovir might aggravate depression and anxiety. Conclusion: Intermittent administration of valacyclovir at a dose of 600 mg daily appears to be an effective prophylaxis for herpes zoster in patients receiving bortezomib.

Key words: Multiple myeloma, Bortezomib, Herpes zoster, Valacyclovir